In myelofibrosis in particular, at this ASH, we had so many updates of different clinical trials. The fact is, that we have at least eight Phase III studies underway for possible approval of new drugs in myelofibrosis. So the field is booming. We hope that over the next 3 to 5 years we’ll have many new drugs for our myelofibrosis patients. It’s very exciting, because we are learning about different biological abnormalities in this condition, leading us to test and develop, hopefully to fruition, all these new drugs that can be, perhaps, combined with JAK inhibitors or used after JAK inhibitors, or tackle problems that we have no medications for, like anemia...
In myelofibrosis in particular, at this ASH, we had so many updates of different clinical trials. The fact is, that we have at least eight Phase III studies underway for possible approval of new drugs in myelofibrosis. So the field is booming. We hope that over the next 3 to 5 years we’ll have many new drugs for our myelofibrosis patients. It’s very exciting, because we are learning about different biological abnormalities in this condition, leading us to test and develop, hopefully to fruition, all these new drugs that can be, perhaps, combined with JAK inhibitors or used after JAK inhibitors, or tackle problems that we have no medications for, like anemia. Anemia is a major problem. So I’m looking forward to seeing what’s going to happen, really, and I’m very optimistic to see new drugs developing in the near future.